Download PDF
Thromb Haemost 1986; 56(01): 063-065
DOI: 10.1055/s-0038-1661604
Original Article
Schattauer GmbH Stuttgart

Cellular Localisation in Placenta of Placental Type Plasminogen Activator Inhibitor

B Åstedt
*   The Research Laboratory of the Department of Obstetrics and Gynaecology, University Hospital, Lund, Sweden
,
I Hägerstrand
The Department of Pathology, University Hospital, Lund, Sweden
,
I Lecander
*   The Research Laboratory of the Department of Obstetrics and Gynaecology, University Hospital, Lund, Sweden
› Author Affiliations
Further Information

Publication History

Received 07 January 1986

Accepted after revision 26 May 1986

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A specific plasminogen activator inhibitor is known to occur in placenta and in pregnancy plasma. Immunohistochemical methods with polyclonal and monoclonal antibodies against the inhibitor were used for its localisation in term placentas. Immunoreactive material was found in the trophoblastic epithelium. It was absent in the stroma of the chorion villi.

Keywords

Placental inhibitor - Trophoblast
 

  • References

  • 1 Åstedt B, Pandolfi M. On release and synthesis of fibrinolytic activators in human organ culture. Eur J Clin Biol Res 1972; 17: 261-267
    PubMedGoogle Scholar
  • 2 Levin EG, Loskutoff DJ. Comparative studies of the fibrinolytic activity of cultured vascular cells. Thromb Res 1979; 15: 869-878
    CrossrefPubMedGoogle Scholar
  • 3 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedGoogle Scholar
  • 4 Astrup T, Permin PM. Fibrinolysis in the animal organism. Nature 1947; 159: 681-682
    PubMedGoogle Scholar
  • 5 Husain SS, Gurewich V, Lipinski B. Purification of a new high molecular weight form of urokinase from urine. Thromb Haemostas 1981; 46: 11 (Abstr.)
    PubMedGoogle Scholar
  • 6 Wun TC, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 7262-7268
    PubMedGoogle Scholar
  • 7 Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain, high molecular weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
    CrossrefPubMedGoogle Scholar
  • 8 Larsson Å, Åstedt B. Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall. J Clin Pathol 1985; 38: 140-145
    CrossrefPubMedGoogle Scholar
  • 9 Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andresen PB, Kristensen P, Dano K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984; 99: 753-758
    CrossrefPubMedGoogle Scholar
  • 10 Camiolo SM, Markus G, Englander LS, Siuta MR, Hobika GH, Kohga S. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Cancer Res 1984; 44: 311-318
    PubMedGoogle Scholar
  • 11 Collen D. Report of the meeting of the subcommittee on fibrinolysis, San Diego, CA, USA, July 13, 1985. Thromb Haemostas 1985; 54: 893
    PubMedGoogle Scholar
  • 12 Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriques H, Jones BN, Barreda C, Watts S, Baker JB. Protease Nexin. J Biol Chem 1985; 260: 7029-7034
    PubMedGoogle Scholar
  • 13 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedGoogle Scholar
  • 14 Loskutoff DJ, Mussoni L. Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. Blood 1983; 62: 62-68
    PubMedGoogle Scholar
  • 15 Juhan-Vague I, Moerman B, de Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
    CrossrefPubMedGoogle Scholar
  • 16 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802: 111-118
    CrossrefPubMedGoogle Scholar
  • 17 Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 802: 99-110
    PubMedGoogle Scholar
  • 18 Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3646
    PubMedGoogle Scholar
  • 19 Kawano T, Morimoto K, Uemura Y. Urokinase inhibitor in human placenta. Nature 1968; 217: 253-254
    CrossrefPubMedGoogle Scholar
  • 20 Åstedt B, Pandolfi M, Nilsson IM. Inhibitory effect of placenta on plasminogen activation in human organ culture. Proc Soc Exp Biol Med 1972; 139: 1421-1424
    CrossrefPubMedGoogle Scholar
  • 21 Åstedt B. Demonstration of significance of placenta in depression of fibrinolytic activity during pregnancy. J Obst Gyn Br Commonw 1972; 79: 205-206
    PubMedGoogle Scholar
  • 22 Åstedt B, Lecander I, Brodin T, Lundblad A, Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985; 53: 122-125
    PubMedGoogle Scholar
  • 23 Lecander I, Åstedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 221-228
    PubMedGoogle Scholar
  • 24 Taylor CR. Immunoperoxidase techniques: practical and theoretical aspects. Arch Pathol Lab Med 1978; 102: 113-121
    PubMedGoogle Scholar
  • 25 Sheppard BL, Bonnar J. Fibrinolysis in decidual spiral arteries in late pregnancy. Thromb Haemostas 1978; 39: 751-758
    PubMedGoogle Scholar
  • 26 Todd AS. Histological localization of fibrinolysin activator. J Path Bact 1959; 78: 281-283
    CrossrefPubMedGoogle Scholar
  • 27 Chapman Jr HA, Stone OL. Characterization of a macrophage-derived plasminogen-activator inhibitor. Biochem J 1985; 230: 109-116
    CrossrefPubMedGoogle Scholar
  • 28 Nilsson IM, Ljungnér H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res) 1985; 290: 1453-1456
    CrossrefPubMedGoogle Scholar